Positive results in the first cohort of four patients treated with Bone Therapeutics' novel allogeneic product for delayed-union fractures BONE THERAPEUTICS, the bone cell therapy company addressing ...
Following an infusion of zoledronate acid in low-risk postmenopausal women, fracture risk reduction emerged only 5-10 years later in a placebo-controlled trial. By year 10, those who received a single ...
Benefits of infrequent zoledronate acid (Reclast) infusions were seen later rather than sooner for low-risk women, a secondary analysis of a randomized trial indicated. Among 1,054 early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results